Posted by Michael Wonder on 05 May 2026
Atossa Therapeutics receives FDA rare paediatric disease designation for (Z)-endoxifen for McCune-Albright syndrome
4 May 2026 - Atossa Therapeutics today announced that the US FDA has granted rare paediatric disease designation to (Z)-endoxifen for the treatment of McCune-Albright syndrome in females.
(Z)-endoxifen is a potent selective oestrogen receptor modulator/degrader with demonstrated activity across multiple mechanisms of interest.
